Word: eying
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...which involved "clear criminal violations," the call by Berkeley and other cities to impeach Bush is about opposition to "judgment calls dealing about very, very serious national security problems." But as a veteran of the sharply divided blogosphere, Volokh should know better than most that criminality is in the eye of the beholder - and Berkeley's exercise in urban overreaching could well have nationwide resonance...
...onto something when early results came in from drug trials on Lucentis. Something so big, in fact, that patients who heard about it were desperate to get the wonder drug - the most effective treatment yet against wet age-related macular degeneration (AMD), the severe form of a chronic eye disease affecting 1.7 million Americans and a leading cause of blindness in the country...
...proposed administering a drug with a similar molecular structure,?also made by Genentech, which was already approved by the FDA - for treating colorectal cancer. Since then an estimated 10,000 people worldwide have given the drug, Avastin, a shot - literally - by taking an injection of it in the eye. And most of them have had very good results with the Lucentis cousin...
...stamp of approval this week. Until now no approved treatment has improved sight in patients with AMD so well. Although Lucentis can't repair the irreversible retina damage that occurs when AMD has gone untreated, it prevents the blood-vessel leakage in the back of the eye that causes damage in the first place, leaving patients with distorted, wavy vision, and eventually a gap in the center of their vision. Up to 40% (depending on the dosage) of those in Lucentis trials improved their eyesight by at least three lines on a vision chart, and nearly all given the drug...
...only problem? Lucentis will likely cost more than 100 times as much as the temporary fix.??A dose of Avastin for the eye costs as little as $13, says Rosenfeld, who is also a lead author on Lucentis trial reports. (Using FDA-approved drugs for "off-label" uses is??common practice, especially in ophthalmology.) Lucentis is almost certain to be pricier when Genentech announces the U.S. sales tag: competing treatments cost up to $3000 per dose...